{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T09:50:09Z","timestamp":1792144209338,"version":"4.4.0"},"reference-count":157,"publisher":"Cambridge University Press (CUP)","issue":"1","license":[{"start":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:00:00Z","timestamp":1792108800000},"content-version":"unspecified","delay-in-days":288,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CNS Spectr."],"published-print":{"date-parts":[[2026]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Social anxiety disorder (SAD) is a common and often chronic psychiatric illness characterized by persistent fear of social or performance situations and associated functional impairment and avoidance. Although multiple pharmacologic treatments have been studied, questions remain regarding optimal sequencing of therapies, long-term treatment strategies, and the management of partial or treatment-resistant illness. This narrative review synthesizes the evidence for pharmacologic treatments for SAD across medication classes, including antidepressants, benzodiazepines, monoamine oxidase inhibitors, GABA-related agents, second-generation antipsychotics, and emerging interventions. It also examines as-needed (PRN) interventions and steroid-based approaches, deprescribing and proposes a definition of treatment-resistant SAD. Randomized controlled trials, open-label studies, and guideline recommendations were reviewed to provide a framework for pharmacologic decision-making. Selective serotonin reuptake inhibitors (SSRIs) and serotonin\u2013norepinephrine reuptake inhibitors (SNRIs) remain the best-supported first-line pharmacotherapies for SAD. Evidence supports switching within or across antidepressant classes and integrating pharmacotherapy with behavioral interventions in patients with incomplete response. Additional treatments, including benzodiazepines, monoamine oxidase inhibitors, pregabalin, and selected augmentation strategies, may be considered for patients with persistent symptoms, although the evidence base is more limited. Data regarding long-term outcomes and treatment-resistant populations remain relatively sparse. While serotonergic antidepressants remain the cornerstone of treatment, optimal management requires individualized sequencing of therapies, integration with behavioral interventions, and consideration of alternative mechanisms in patients with incomplete response. Future studies should prioritize comparative effectiveness, long-term outcomes, and interventions for treatment-resistant SAD.<\/jats:p>","DOI":"10.1017\/s1092852926101254","type":"journal-article","created":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T09:36:23Z","timestamp":1792143383000},"source":"Crossref","is-referenced-by-count":0,"title":["Pharmacotherapy for social anxiety disorder: An evidence-based treatment review"],"prefix":"10.1017","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7526-2641","authenticated-orcid":false,"given":"Jeffrey Robert","family":"Strawn","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02p72h367","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Cincinnati College of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen M.","family":"Stahl","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/058c0g260","id-type":"ROR","asserted-by":"publisher"}],"name":"Neuroscience Education Institute"},{"id":[{"id":"https:\/\/ror.org\/0168r3w48","id-type":"ROR","asserted-by":"publisher"}],"name":"University of California San Diego"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azmi","family":"Nasser","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01fkvbf41","id-type":"ROR","asserted-by":"publisher"}],"name":"VistaGen Therapeutics Inc"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5800-0378","authenticated-orcid":false,"given":"Andrew J.","family":"Cutler","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/040kfrw16","id-type":"ROR","asserted-by":"publisher"}],"name":"SUNY Upstate Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e1rcio","family":"Bernik","sequence":"additional","affiliation":[{"name":"University of Sao Paulo Medical School"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"56","published-online":{"date-parts":[[2026,10,16]]},"reference":[{"key":"S1092852926101254_r117","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2005.07.005"},{"key":"S1092852926101254_r121","doi-asserted-by":"publisher","DOI":"10.1017\/S109285292000190X"},{"key":"S1092852926101254_r123","doi-asserted-by":"publisher","DOI":"10.1002\/hup.2892"},{"key":"S1092852926101254_r148","doi-asserted-by":"publisher","DOI":"10.1159\/000491524"},{"key":"S1092852926101254_r54","doi-asserted-by":"publisher","DOI":"10.1017\/9781009642187"},{"key":"S1092852926101254_r16","doi-asserted-by":"publisher","DOI":"10.1002\/npr2.12365"},{"key":"S1092852926101254_r75","article-title":"Optimizing benzodiazepine treatment of anxiety disorders","volume":"22","author":"Strawn","year":"2023","journal-title":"Curr Psychiatr Ther"},{"key":"S1092852926101254_r157","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2025.02.092"},{"key":"S1092852926101254_r83","first-page":"244","article-title":"Double-blind, placebo-controlled assessment of combined clonazepam with paroxetine compared with paroxetine monotherapy for generalized social anxiety disorder","volume":"65","author":"Seedat","year":"2004","journal-title":"J Clin Psychiatry"},{"key":"S1092852926101254_r72","doi-asserted-by":"publisher","DOI":"10.1097\/01.jcp.0000186871.04984.8d"},{"key":"S1092852926101254_r141","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-023-01294-8"},{"key":"S1092852926101254_r55","doi-asserted-by":"publisher","DOI":"10.1097\/FPC.0000000000000392"},{"key":"S1092852926101254_r64","doi-asserted-by":"publisher","DOI":"10.1111\/appy.12203"},{"key":"S1092852926101254_r107","doi-asserted-by":"publisher","DOI":"10.1177\/026988110201600412"},{"key":"S1092852926101254_r51","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.31.3.289"},{"key":"S1092852926101254_r112","doi-asserted-by":"publisher","DOI":"10.1016\/j.psyneuen.2020.104612"},{"key":"S1092852926101254_r136","doi-asserted-by":"publisher","DOI":"10.1007\/BF02246094"},{"key":"S1092852926101254_r3","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.62.6.593"},{"key":"S1092852926101254_r71","doi-asserted-by":"publisher","DOI":"10.1097\/00004850-200211000-00008"},{"key":"S1092852926101254_r100","doi-asserted-by":"publisher","DOI":"10.2147\/nedt.2007.3.2.237"},{"key":"S1092852926101254_r134","doi-asserted-by":"publisher","DOI":"10.1080\/08039480310002110"},{"key":"S1092852926101254_r36","first-page":"CD001206","article-title":"Pharmacotherapy for social anxiety disorder (SAnD)","volume":"2019","author":"Williams","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"S1092852926101254_r140","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1017\/S1092852922000906","article-title":"The prescriber\u2019s guide to classic MAO inhibitors (phenelzine, tranylcypromine, isocarboxazid) for treatment-resistant depression","volume":"28","author":"Abdelmoemin","year":"2023","journal-title":"CNS Spectr"},{"key":"S1092852926101254_r154","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.164.5.652"},{"key":"S1092852926101254_r113","doi-asserted-by":"publisher","DOI":"10.1016\/j.psyneuen.2016.07.203"},{"key":"S1092852926101254_r46","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.62.2.190"},{"key":"S1092852926101254_r25","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.186.3.222"},{"key":"S1092852926101254_r152","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-199810000-00004"},{"key":"S1092852926101254_r28","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1176\/ajp.154.4.516","article-title":"19F magnetic resonance spectroscopy investigation in vivo of acute and steady-state brain fluvoxamine levels in obsessive-compulsive disorder","volume":"154","author":"Strauss","year":"1997","journal-title":"Am J Psychiatry"},{"key":"S1092852926101254_r93","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2008.06.025"},{"key":"S1092852926101254_r128","doi-asserted-by":"publisher","DOI":"10.1017\/S0033291709991231"},{"key":"S1092852926101254_r26","doi-asserted-by":"publisher","DOI":"10.1002\/da.20014"},{"key":"S1092852926101254_r43","first-page":"402","article-title":"A double-blind placebo-controlled trial of paroxetine in the management of social phobia (social anxiety disorder) in South Africa","volume":"89","author":"Stein","year":"1999","journal-title":"S Afr Med J"},{"key":"S1092852926101254_r9","doi-asserted-by":"publisher","DOI":"10.1007\/s00127-003-0720-6"},{"key":"S1092852926101254_r69","doi-asserted-by":"publisher","DOI":"10.1017\/neu.2020.6"},{"key":"S1092852926101254_r29","doi-asserted-by":"publisher","DOI":"10.1007\/BF02244762"},{"key":"S1092852926101254_r61","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.182.4.312"},{"key":"S1092852926101254_r129","doi-asserted-by":"publisher","DOI":"10.1002\/wps.21177"},{"key":"S1092852926101254_r84","first-page":"5","volume-title":"Essentials of Clinical Psychopharmacology","author":"Nelson","year":"2017"},{"key":"S1092852926101254_r8","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.64.8.903"},{"key":"S1092852926101254_r108","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v66n0420b"},{"key":"S1092852926101254_r147","doi-asserted-by":"publisher","DOI":"10.1001\/archgenpsychiatry.2010.170"},{"key":"S1092852926101254_r56","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1176\/ajp.152.9.1368","article-title":"Sertraline for social phobia: a double-blind, placebo-controlled crossover study","volume":"152","author":"Katzelnick","year":"1995","journal-title":"Am J Psychiatry"},{"key":"S1092852926101254_r144","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2019.00099"},{"key":"S1092852926101254_r52","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-022-01246-4"},{"key":"S1092852926101254_r10","doi-asserted-by":"publisher","DOI":"10.1007\/BF02190407"},{"key":"S1092852926101254_r77","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-199312000-00008"},{"key":"S1092852926101254_r114","doi-asserted-by":"publisher","DOI":"10.9758\/cpn.2019.17.1.1"},{"key":"S1092852926101254_r155","doi-asserted-by":"publisher","DOI":"10.1002\/npr2.12275"},{"key":"S1092852926101254_r98","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v58n0405"},{"key":"S1092852926101254_r76","doi-asserted-by":"publisher","DOI":"10.1017\/S1092852921000870"},{"key":"S1092852926101254_r94","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-199708000-00002"},{"key":"S1092852926101254_r102","doi-asserted-by":"publisher","DOI":"10.1097\/YIC.0b013e32834519bd"},{"key":"S1092852926101254_r17","doi-asserted-by":"publisher","DOI":"10.1186\/1471-244X-14-S1-S1"},{"key":"S1092852926101254_r126","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2016.07.018"},{"key":"S1092852926101254_r21","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.162.6.1179"},{"key":"S1092852926101254_r111","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-021-01556-8"},{"key":"S1092852926101254_r13","doi-asserted-by":"publisher","DOI":"10.1037\/0022-006X.76.1.72"},{"key":"S1092852926101254_r103","doi-asserted-by":"publisher","DOI":"10.1097\/YIC.0b013e3283491fd5"},{"key":"S1092852926101254_r85","first-page":"4","article-title":"Mechanism of action of antidepressant medications","volume":"60","author":"Feighner","year":"1999","journal-title":"J Clin Psychiatry"},{"key":"S1092852926101254_r139","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00934-X"},{"key":"S1092852926101254_r115","doi-asserted-by":"publisher","DOI":"10.1186\/s40360-025-00996-y"},{"key":"S1092852926101254_r49","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v65n0213"},{"key":"S1092852926101254_r20","first-page":"e20243878","article-title":"Brazilian psychiatric association guidelines for the treatment of social anxiety disorder","volume":"47","author":"Balda\u00e7ara","year":"2025","journal-title":"Braz J Psychiatry"},{"key":"S1092852926101254_r86","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.13r08672"},{"key":"S1092852926101254_r42","doi-asserted-by":"publisher","DOI":"10.1001\/jama.280.8.708"},{"key":"S1092852926101254_r58","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v64n0708"},{"key":"S1092852926101254_r137","volume-title":"Sleep Disorders: Diagnosis and Therapeutics","author":"Bentu\u00e9-Ferrer","year":"2008"},{"key":"S1092852926101254_r149","doi-asserted-by":"publisher","DOI":"10.1016\/j.addbeh.2018.08.027"},{"key":"S1092852926101254_r45","doi-asserted-by":"publisher","DOI":"10.1016\/j.janxdis.2007.03.001"},{"key":"S1092852926101254_r7","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.58.3.251"},{"key":"S1092852926101254_r11","doi-asserted-by":"publisher","DOI":"10.1017\/S0033291799008375"},{"key":"S1092852926101254_r68","doi-asserted-by":"publisher","DOI":"10.1002\/hup.602"},{"key":"S1092852926101254_r146","doi-asserted-by":"publisher","DOI":"10.1017\/S1092852900006933"},{"key":"S1092852926101254_r105","doi-asserted-by":"publisher","DOI":"10.1038\/npp.2008.69"},{"key":"S1092852926101254_r15","doi-asserted-by":"publisher","DOI":"10.1007\/s10802-022-00996-0"},{"key":"S1092852926101254_r1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.2012.01886.x"},{"key":"S1092852926101254_r40","doi-asserted-by":"publisher","DOI":"10.1017\/S0033291798007879"},{"key":"S1092852926101254_r79","doi-asserted-by":"publisher","DOI":"10.1017\/S1092852924000142"},{"key":"S1092852926101254_r96","doi-asserted-by":"publisher","DOI":"10.1001\/archgenpsychiatry.2010.11"},{"key":"S1092852926101254_r41","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.175.2.120"},{"key":"S1092852926101254_r48","doi-asserted-by":"publisher","DOI":"10.1159\/000447013"},{"key":"S1092852926101254_r50","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2903"},{"key":"S1092852926101254_r138","doi-asserted-by":"publisher","DOI":"10.1097\/00004850-199409000-00002"},{"key":"S1092852926101254_r142","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(96)90134-4"},{"key":"S1092852926101254_r130","doi-asserted-by":"publisher","DOI":"10.1159\/000547926"},{"key":"S1092852926101254_r62","first-page":"e228","article-title":"Short-term dynamic psychotherapy versus sertraline in treatment of social phobia","volume":"9","author":"Nader-Mohammadi Moghadam","year":"2015","journal-title":"Iran J Psychiatry Behav Sci"},{"key":"S1092852926101254_r132","doi-asserted-by":"publisher","DOI":"10.1002\/hup.1165"},{"key":"S1092852926101254_r18","doi-asserted-by":"publisher","DOI":"10.30773\/pi.2017.05.01"},{"key":"S1092852926101254_r95","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.55.12.1133"},{"key":"S1092852926101254_r30","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.156.5.756"},{"key":"S1092852926101254_r88","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-199804000-00005"},{"key":"S1092852926101254_r38","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-199606000-00005"},{"key":"S1092852926101254_r60","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0205809"},{"key":"S1092852926101254_r31","doi-asserted-by":"publisher","DOI":"10.1097\/01.jcp.0000104906.75206.8b"},{"key":"S1092852926101254_r53","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2025.1362"},{"key":"S1092852926101254_r67","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13788"},{"key":"S1092852926101254_r80","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2015.0351"},{"key":"S1092852926101254_r97","first-page":"239","article-title":"Phenelzine and exposure in the treatment of phobias","volume":"16","author":"Solyom","year":"1981","journal-title":"Biol Psychiatry"},{"key":"S1092852926101254_r37","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(14)70329-3"},{"key":"S1092852926101254_r118","first-page":"1","article-title":"Kava extract versus placebo for treating anxiety [systematic review]","author":"Pittler","year":"2005","journal-title":"Cochrane Database Syst Rev"},{"key":"S1092852926101254_r87","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.142.2.174"},{"key":"S1092852926101254_r12","doi-asserted-by":"publisher","DOI":"10.1037\/a0018697"},{"key":"S1092852926101254_r65","doi-asserted-by":"publisher","DOI":"10.1002\/gps.4088"},{"key":"S1092852926101254_r81","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.22106"},{"key":"S1092852926101254_r122","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2014.12101342"},{"key":"S1092852926101254_r66","doi-asserted-by":"publisher","DOI":"10.1017\/S1092852900000365"},{"key":"S1092852926101254_r27","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2016.1146663"},{"key":"S1092852926101254_r125","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1127792"},{"key":"S1092852926101254_r2","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.57.9.859"},{"key":"S1092852926101254_r153","doi-asserted-by":"publisher","DOI":"10.1097\/00005053-199612000-00003"},{"key":"S1092852926101254_r73","doi-asserted-by":"publisher","DOI":"10.1097\/YIC.0b013e32833a4d71"},{"key":"S1092852926101254_r116","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsycho.2017.05.015"},{"key":"S1092852926101254_r4","doi-asserted-by":"publisher","DOI":"10.1002\/da.21924"},{"key":"S1092852926101254_r120","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2007.02932.x"},{"key":"S1092852926101254_r39","first-page":"217","volume-title":"ECDEU Assessment Manual for Psychopharmacology","author":"Guy","year":"1976"},{"key":"S1092852926101254_r24","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.59.5.425"},{"key":"S1092852926101254_r19","doi-asserted-by":"publisher","DOI":"10.1007\/s00406-021-01324-1"},{"key":"S1092852926101254_r92","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.49.4.290"},{"key":"S1092852926101254_r104","doi-asserted-by":"publisher","DOI":"10.1002\/hup.846"},{"key":"S1092852926101254_r119","doi-asserted-by":"publisher","DOI":"10.1002\/ptr.1006"},{"key":"S1092852926101254_r133","doi-asserted-by":"publisher","DOI":"10.1097\/00004850-199907000-00006"},{"key":"S1092852926101254_r156","doi-asserted-by":"publisher","DOI":"10.1080\/15622975.2022.2086296"},{"key":"S1092852926101254_r145","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2023.0063"},{"key":"S1092852926101254_r127","doi-asserted-by":"publisher","DOI":"10.1037\/a0020968"},{"key":"S1092852926101254_r150","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.19com12794"},{"key":"S1092852926101254_r143","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2017.17050550"},{"key":"S1092852926101254_r32","doi-asserted-by":"publisher","DOI":"10.1017\/S146114570300364X"},{"key":"S1092852926101254_r57","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.158.2.275"},{"key":"S1092852926101254_r5","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2005.04.002"},{"key":"S1092852926101254_r22","first-page":"14","article-title":"Social anxiety disorder clinical course and outcome: review of Harvard\/Brown anxiety research project (HARP) findings","volume":"67","author":"Keller","year":"2006","journal-title":"J Clin Psychiatry"},{"key":"S1092852926101254_r47","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.158.10.1725"},{"key":"S1092852926101254_r151","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1990.01810220015002"},{"key":"S1092852926101254_r109","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2007.06.027"},{"key":"S1092852926101254_r124","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.2025.84"},{"key":"S1092852926101254_r74","doi-asserted-by":"publisher","DOI":"10.1002\/da.22702"},{"key":"S1092852926101254_r78","doi-asserted-by":"publisher","DOI":"10.1016\/S0887-6185(00)00027-X"},{"key":"S1092852926101254_r14","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2019.0248"},{"key":"S1092852926101254_r44","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v63n0113"},{"key":"S1092852926101254_r110","doi-asserted-by":"publisher","DOI":"10.1016\/j.psyneuen.2023.106372"},{"key":"S1092852926101254_r33","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.61.10.1005"},{"key":"S1092852926101254_r131","doi-asserted-by":"publisher","DOI":"10.1186\/1745-0179-2-35"},{"key":"S1092852926101254_r91","first-page":"252","article-title":"Pharmacotherapy of social phobia: an interim report of a placebo-controlled comparison of phenelzine and atenolol","volume":"49","author":"Liebowitz","year":"1988","journal-title":"J Clin Psychiatry"},{"key":"S1092852926101254_r34","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-200206000-00005"},{"key":"S1092852926101254_r70","article-title":"A 12-week double-blind, placebo-controlled, flexible-dose trial of vilazodone in generalized social anxiety disorder","volume":"17","author":"Careri","year":"2015","journal-title":"Prim Care Companion CNS Disord"},{"key":"S1092852926101254_r90","doi-asserted-by":"publisher","DOI":"10.1017\/S0033291700046419"},{"key":"S1092852926101254_r6","doi-asserted-by":"publisher","DOI":"10.1111\/j.0065-1591.2000.acp29-03.x"},{"key":"S1092852926101254_r63","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaac.2015.01.008"},{"key":"S1092852926101254_r135","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2013.12101353"},{"key":"S1092852926101254_r35","doi-asserted-by":"publisher","DOI":"10.1037\/0022-006X.71.6.1058"},{"key":"S1092852926101254_r23","doi-asserted-by":"publisher","DOI":"10.1002\/hup.436"},{"key":"S1092852926101254_r59","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.179.1.23"},{"key":"S1092852926101254_r82","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.58.7.681"},{"key":"S1092852926101254_r89","doi-asserted-by":"publisher","DOI":"10.1016\/0165-0327(91)90041-P"},{"key":"S1092852926101254_r106","volume-title":"A Placebo Controlled Trial of Cariprazine in Social Anxiety","author":"Careri","year":"2024"},{"key":"S1092852926101254_r99","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-199908000-00010"},{"key":"S1092852926101254_r101","doi-asserted-by":"publisher","DOI":"10.1097\/01.jcp.0000117423.05703.e7"}],"container-title":["CNS Spectrums"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S1092852926101254","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T09:36:27Z","timestamp":1792143387000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S1092852926101254\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":157,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026]]}},"alternative-id":["S1092852926101254"],"URL":"https:\/\/doi.org\/10.1017\/s1092852926101254","relation":{},"ISSN":["1092-8529","2165-6509"],"issn-type":[{"value":"1092-8529","type":"print"},{"value":"2165-6509","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"article-number":"e45"}}